PRINCETON, N.J. and BRUSSELS, Belgium, June 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) and Euroscreen s.a. announced today the completion of a license and research agreement for the exclusive worldwide development and commercialization of antibody-based products against certain targets for various diseases, including inflammatory and autoimmune conditions. Medarex intends to use its UltiMAb® technology to create antibodies to targets provided by Euroscreen.
